Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
31.75
-0.64 (-1.98%)
Apr 29, 2026, 11:53 AM EDT - Market open
Viking Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 165.81 | 26.68 | 55.52 | 36.63 | 26.37 | Upgrade
|
| Short-Term Investments | 539.93 | 875.94 | 306.56 | 118.85 | 175.73 | Upgrade
|
| Cash & Short-Term Investments | 705.74 | 902.61 | 362.08 | 155.49 | 202.1 | Upgrade
|
| Cash Growth | -21.81% | 149.29% | 132.87% | -23.07% | -18.63% | Upgrade
|
| Prepaid Expenses | 1.81 | 1.13 | 2.52 | 3.41 | 0.62 | Upgrade
|
| Other Current Assets | 8.05 | 3.48 | 2.62 | 8.14 | 7.81 | Upgrade
|
| Total Current Assets | 715.6 | 907.22 | 367.23 | 167.04 | 210.53 | Upgrade
|
| Property, Plant & Equipment | 0.09 | 1 | 1.13 | 1.42 | 0.03 | Upgrade
|
| Long-Term Deferred Charges | - | 0.06 | 0.11 | 0.04 | 0.08 | Upgrade
|
| Other Long-Term Assets | 0.05 | 0.05 | 0.03 | 0.03 | 0.03 | Upgrade
|
| Total Assets | 715.73 | 908.32 | 368.49 | 168.53 | 210.66 | Upgrade
|
| Accounts Payable | 53.25 | 9.81 | 7.51 | 8.53 | 1.44 | Upgrade
|
| Accrued Expenses | 23.28 | 17.11 | 11.3 | 13.11 | 7.31 | Upgrade
|
| Current Portion of Leases | 0.14 | 0.49 | 0.32 | 0.3 | 0.03 | Upgrade
|
| Total Current Liabilities | 76.67 | 27.41 | 19.14 | 21.95 | 8.78 | Upgrade
|
| Long-Term Leases | - | 0.63 | 0.94 | 1.26 | - | Upgrade
|
| Total Liabilities | 76.67 | 28.04 | 20.07 | 23.21 | 8.78 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,486 | 1,369 | 733.55 | 445.27 | 425.61 | Upgrade
|
| Retained Earnings | -847.55 | -487.91 | -377.94 | -292.05 | -223.18 | Upgrade
|
| Treasury Stock | - | - | -6.8 | -6.8 | - | Upgrade
|
| Comprehensive Income & Other | 0.38 | -0.79 | -0.39 | -1.1 | -0.55 | Upgrade
|
| Shareholders' Equity | 639.06 | 880.28 | 348.42 | 145.32 | 201.88 | Upgrade
|
| Total Liabilities & Equity | 715.73 | 908.32 | 368.49 | 168.53 | 210.66 | Upgrade
|
| Total Debt | 0.14 | 1.12 | 1.26 | 1.56 | 0.03 | Upgrade
|
| Net Cash (Debt) | 705.6 | 901.49 | 360.82 | 153.92 | 202.07 | Upgrade
|
| Net Cash Growth | -21.73% | 149.85% | 134.42% | -23.83% | -18.53% | Upgrade
|
| Net Cash Per Share | 6.26 | 8.27 | 3.82 | 2.00 | 2.62 | Upgrade
|
| Filing Date Shares Outstanding | 115.55 | 112.25 | 100.49 | 78.42 | 78.36 | Upgrade
|
| Total Common Shares Outstanding | 114.79 | 111.57 | 100.11 | 78.26 | 78.25 | Upgrade
|
| Working Capital | 638.93 | 879.8 | 348.09 | 145.09 | 201.75 | Upgrade
|
| Book Value Per Share | 5.57 | 7.89 | 3.48 | 1.86 | 2.58 | Upgrade
|
| Tangible Book Value | 639.06 | 880.28 | 348.42 | 145.32 | 201.88 | Upgrade
|
| Tangible Book Value Per Share | 5.57 | 7.89 | 3.48 | 1.86 | 2.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.